New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
December 4, 2012
16:15 EDTTHRXTheravance initiates Phase 2 study with TD-9855 for treatment of fibromyalgia
announced today initiation of a fibromyalgia Phase 2 study with TD-9855. TD-9855 is an investigational norepinephrine and serotonin reuptake inhibitor for the treatment of central nervous system conditions such as chronic pain and Attention-Deficit/Hyperactivity Disorder.
News For THRX From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
February 18, 2015
16:40 EDTTHRXTheravance reports Q4 EPS (14c), consensus (15c)
Reports Q4 revenue $7.3M, consensus $5.42M.
15:35 EDTTHRXNotable companies reporting after market close
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use